Form 4: BlackRock Health Sciences Portfolio Manager Reports Routine Share Transactions

H. Erin Xie, a Portfolio Manager at BlackRock Health Sciences Trust, reported the sale of common stock and the grant and vesting of phantom shares as part of a pre-arranged 10b5-1 plan.

Summary

• H. Erin Xie, a Portfolio Manager for BlackRock Health Sciences Trust (BME), reported transactions on January 30, 2026.
• These transactions included the acquisition and subsequent disposition of 11,449.5087 shares of common stock at a price of $41.87 per share, resulting in 0 direct beneficial ownership of common stock.
• The reporting person also acquired 6,379.1521 new phantom shares, which are the economic equivalent of common stock, vest in equal installments over three years, and are payable in cash.
• Additionally, previous grants of phantom shares from January 31, 2025 (3,451.5026 shares), January 31, 2024 (3,013.3991 shares), and January 31, 2023 (4,984.607 shares) vested and were settled.
• All reported transactions were made pursuant to a Rule 10b5-1 pre-arranged trading plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a largely neutral filing. While there was a disposition of common stock, it was executed under a pre-arranged 10b5-1 plan, mitigating any negative signal. The new grant of phantom shares is a positive for the insider's future compensation.

Positives

• The reporting person received a new grant of 6,379.1521 phantom shares, which aligns their future compensation with the company's performance.
• The vesting of previous phantom share grants represents scheduled compensation, reflecting the fulfillment of prior incentive awards.

Negatives

• The reporting person's direct beneficial ownership of common stock is 0 shares following the reported transactions, indicating a full disposition of the acquired shares.

Future Outlook

NA

Management Comments

• A phantom share is the economic equivalent of one share of common stock and, subject to the applicable vesting requirements, becomes payable in cash.

Industry Context

StockSavvy.ai notes that insider transaction reports like this Form 4 are routine disclosures for publicly traded companies, providing transparency into executive and director stock ownership changes. The use of a 10b5-1 plan for the common stock disposition indicates a pre-scheduled transaction, which is a common practice to mitigate concerns about trading on material non-public information.

Stakeholder Impact

• Shareholders: The disposition of common stock by a portfolio manager, even if pre-planned, could be viewed with slight caution, though the 10b5-1 plan mitigates concerns. The new grant of phantom shares aligns the manager's long-term interests with shareholder value.

Key Dates

Recommendation

The filing details routine insider transactions, including a pre-planned sale of common stock and the grant and vesting of phantom shares. These events are typical for executive compensation and do not provide new fundamental insights into the company's performance or strategic direction that would warrant a change in investment recommendation. Investors should hold and monitor future company performance and broader market trends.

Keywords

BlackRock Health Sciences Trust, BME, SEC Form 4, Insider Trading, H. Erin Xie, Portfolio Manager, Common Stock, Phantom Shares, 10b5-1 Plan, Equity Compensation, Insider Transactions